VTVT · vTv Therapeutics Inc. · Metrics
Market Cap
$111.01M
Shares
3.95M
Volume · Oct 20
21.21K
Avg daily vol (3M)
60.6K
VTVT metrics
56 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$27.85
Market cap
$111.01M
Price action
20 metricsPrice change (1W)
-11.6%
Price change (30D)
-13.9%
Price change (3M)
-16.8%
Price change (6M)
-28.6%
Price change (YTD)
-32.6%
Price change (1Y)
+33.2%
Trailing year
Price change (5Y)
—
52-week high
$42.72
52-week low
$20.61
Change from 52-week high
-36.9%
Change from 52-week low
+30.7%
Annualized volatility
72.4%
Annualized volatility (3M)
41.6%
Beta
1.1
RSI (14D)
33.9
Price vs SMA 50
-14.0%
Price vs SMA 200
-21.0%
Avg volume (3M)
62,035
Relative volume
0.3
Average dollar volume
$1.99M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
3.95M
Valuation
12 metricsP / E (TTM)
55.4
Trailing earnings · reciprocal yield 1.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.9×
reciprocal yield 34.2%
P / book
1.4
reciprocal yield 73.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-25.1%
Trailing 12 months
Net margin
-12.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$9.25M
Net income (TTM)
−$4.76M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$36.84M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-6.0%
Return on assets
-5.4%
Debt / equity
—
Current ratio
12.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
12.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$86.64M
Total assets
$87.59M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$16.76M
Capital expenditures (TTM)
—
R&D (TTM)
$28.68M
SG&A (TTM)
—
Stock compensation (TTM)
$5.15M
R&D / revenue
77.8%
Stock compensation / revenue
14.0%
Ownership (13F)
9 metrics13F filers
45
13F filer change QoQ
+10
Institutional ownership
40.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+12.3%
Holder tenure
7.3
Price vs estimated holder cost
+54.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
3.2%
Short interest
3 metricsShort interest
4.0%
Latest settlement · 3.3 days to cover
Days to cover
3.3d
Short-squeeze score
49 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—